New York, October 8 (Reuters) / PRNewswire / -- Pomerantz LLP represents investors of Novartis Corporation ( Novartis AG , hereinafter referred to as “ Novartis ” or “the Company” ) ( NYSE : NVS ). Interested investors may contact Danielle Peyton at the email address [ email protected ], telephone 646-581-9980, extension 7980.

This investigation involves whether Novartis and some of its executives and/or directors have engaged in securities fraud or other illegal business practices.

[Click here to learn about joining the class action.]

On September 8, 2026, Novartis issued a press release stating that in the global Phase 3 study evaluating del-desiran for patients with type 1 dystrophic myotonia (DM1), there was no statistically significant improvement in the primary endpoint of video-assessed hand opening time (vHOT) compared to placebo. The company noted that vHOT is a new indicator for measuring hand muscle stiffness.

Affected by this news, the price of Novartis American Depository Receipts ( ADS ) fell by $22.29 per ADS on September 8, 2026, a decrease of 13.93%, closing at $137.70 per ADS.

Pomerantz LLP has offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, and is recognized as one of the top law firms in the fields of corporate law, securities law, and class action litigation. The firm was founded by the late Abraham L Pomerantz, who was known as the "dean" of the class action litigation community and pioneered the field of securities class actions. More than 85 years have passed since then, and Pomerantz continues this tradition, dedicated to protecting the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has secured millions of dollars in compensation for its class members. For more information, please refer to www.pomlaw.com.

Lawyer advertisement. Past results do not guarantee similar outcomes.

Contact:

Danielle Peyton

Pomerantz LLP

[ email protected ]

646-581-9980 ext . 7980